Literature DB >> 19279088

Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

Jia Liu1, Sonia Wennier, Mary Reinhard, Edward Roy, Amy MacNeill, Grant McFadden.   

Abstract

Myxoma virus (MYXV) is a poxvirus pathogenic only for European rabbits, but its permissiveness in human cancer cells gives it potential as an oncolytic virus. A recombinant MYXV expressing both the tdTomato red fluorescent protein and interleukin-15 (IL-15) (vMyx-IL-15-tdTr) was constructed. Cells infected with vMyx-IL-15-tdTr secreted bioactive IL-15 and had in vitro replication kinetics similar to that of wild-type MYXV. To determine the safety of this virus for future oncolytic studies, we tested its pathogenesis in European rabbits. In vivo, vMyx-IL-15-tdTr no longer causes lethal myxomatosis. Thus, ectopic IL-15 functions as an antiviral cytokine in vivo, and vMyx-IL-15-tdTr is a safe candidate for animal studies of oncolytic virotherapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19279088      PMCID： PMC2681933          DOI： 10.1128/JVI.00204-09

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  37 in total

1.  The complete DNA sequence of myxoma virus.

Authors:  C Cameron; S Hota-Mitchell; L Chen; J Barrett; J X Cao; C Macaulay; D Willer; D Evans; G McFadden
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

Review 2.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

Authors:  T A Waldmann; S Dubois; Y Tagaya
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

3.  Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.

Authors:  Katja Mueller; Oliver Schweier; Hanspeter Pircher
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

4.  IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Authors:  Sandra A Calarota; Anlan Dai; Jeffrey N Trocio; David B Weiner; Franco Lori; Julianna Lisziewicz
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

5.  Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice.

Authors:  L P Perera; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

6.  Control of homeostasis of CD8+ memory T cells by opposing cytokines.

Authors:  C C Ku; M Murakami; A Sakamoto; J Kappler; P Marrack
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

7.  Coevolution of host and virus: cellular localization of virus in myxoma virus infection of resistant and susceptible European rabbits.

Authors:  S M Best; S V Collins; P J Kerr
Journal:  Virology       Date:  2000-11-10       Impact factor: 3.616

8.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

9.  Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model.

Authors:  Grzegorz W Basak; Lukasz Zapala; Piotr J Wysocki; Andrzej Mackiewicz; Marek Jakóbisiak; Witold Lasek
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

10.  Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.

Authors:  Xiao Wang; Xinyu Zhang; Youming Kang; Huali Jin; Xiaogang Du; Gan Zhao; Yang Yu; Jinyao Li; Baowei Su; Chang Huang; Bin Wang
Journal:  Vaccine       Date:  2008-05-06       Impact factor: 3.641
View more
  24 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors:  Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

3.  Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits.

Authors:  Jia Liu; Sonia Wennier; Nissin Moussatche; Mary Reinhard; Richard Condit; Grant McFadden
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.

Authors:  Yang Yan; Songyan Li; Tingting Jia; Xiaohui Du; Yingxin Xu; Yunshan Zhao; Li Li; Kai Liang; Wentao Liang; Huiwei Sun; Rong Li
Journal:  Tumour Biol       Date:  2015-01-28

Review 5.  The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.

Authors:  Jia Liu; Sonia Wennier; Grant McFadden
Journal:  Microbes Infect       Date:  2010-09-09       Impact factor: 2.700

6.  Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

Authors:  Rosalinda A Doty; Jia Liu; Grant McFadden; Edward J Roy; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2013-01

7.  Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

Authors:  Nancy Y Villa; Swarna Bais; Winnie M Chan; Amy M Meacham; Elizabeth Wise; Masmudur M Rahman; Jan S Moreb; Emma H Rosenau; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Cytotherapy       Date:  2016-03       Impact factor: 5.414

8.  Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

Authors:  Sonia Tusell Wennier; Jia Liu; Shoudong Li; Masmudur M Rahman; Mahmoud Mona; Grant McFadden
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

9.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019

10.  Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination.

Authors:  A M Wolfe; K M Dunlap; A C Smith; M Y Bartee; E Bartee
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.